

PHARMACIST PAXLOVID PRESCRIBING GUIDE

Risk Factors for Severe COVID-19

- Older Age (≥65 years old)
- Respiratory Disease
- Cardiovascular Disease
- Diabetes
- Obesity (BMI ≥ 30kg/m²)
- Overweight (BMI > 25)
- Chronic Kidney Disease
- Sickle Cell Disease
- Immunocompromised


Does the patient meet ALL of the following eligibility criteria?

- Mild-to-moderate COVID-19 with symptom onset within the past five days
- 12 years of age or older
- Weigh 40 kg or more
- High risk for progression to severe COVID-19

*Home antigen tests are acceptable.
Testing does not need to be performed at the pharmacy*

Mild to Moderate Symptoms

- Fever
- Cough
- Sore throat
- Fatigue
- Headache
- Loss of smell/ taste
- Congestion
- Muscle pain
- Nausea
- Vomiting
- Diarrhea



Paxlovid Standard Dose
300mg nirmatrelvir (two 150mg tablets) + 100mg ritonavir twice a day for 5 days

Paxlovid Renal Dose
150mg nirmatrelvir + 100mg ritonavir twice a day for 5 days

Prescribing & Dispensing

- Prescribing pharmacists are responsible for mandatory reporting of all serious adverse events and medication errors potentially related to Paxlovid **within 7 calendar days** from their awareness of the event using FDA Form 3500
- [Complete and submit the MedWatch report online](#)
- Prescribing pharmacists are also asked to submit a copy of the report to [Pfizer Safety Reporting](#)
- A copy of the [Fact Sheet for Patients, Parents, and Caregivers](#) must be provided with Paxlovid

Paxlovid Contraindications

- Paxlovid is a strong inhibitor of CYP3A and may increase plasma concentrations of drugs that are primarily metabolized by CYP3A
- Paxlovid is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions

Paxlovid cannot be started immediately after discontinuation of any of the following medications due to the sustained CYP3A induction of recently discontinued inducers

- Apalutamide
- Carbamazepine
- Lumacaftor/ivacaftor
- Phenobarbital
- Primidone
- Phenytoin
- Rifampin
- St. John's Wort

Notable Drug-Drug Interactions

- Alfuzosin
- Amiodarone
- Clozapine
- Colchicine
- Dihydroergotamine
- Dronedarone
- Eletriptan
- Eplerenone
- Ergotamine
- Finereone
- Flecainide
- Flibanserin
- Ivabradine
- Lomitapide
- Lovastatin
- Lurasidone
- Methylergonovine
- Midazolam, oral
- Naloxegol
- Pethidine
- Pimozide
- Propadenone
- Quinidone
- Ranolazine
- Sildenafil when used for pulmonary arterial hypertension (PAH)
- Silodosin
- Simvastatin
- Triazolam
- Tolvaptan
- Ubrogepant
- Voclosporin

**This list may not be all inclusive*

Resources for Evaluating Drug Interactions

- [Fact Sheet for Healthcare Providers](#)
- [University of Liverpool COVID-19 Drug Interactions Checker](#)
- [COVID-19 Advisory for Ontario What Prescribers and Pharmacists Need to Know](#)

Other Resources

- [ASHP Paxlovid Resources](#)
- [NIH COVID-19 Treatment Guidelines](#)
- [CDC: COVID-19](#)
- [Test to Treat Locator](#)
- [PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers](#)
- [AHFS Nirmatrelvir Monograph](#)